Investigating Pembrolizumab Alone or With Chemotherapy for Non-Small Cell Lung Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This umbrella master protocol study aims to screen participants with non-small cell lung cancer (NSCLC) for enrollment into one of seven substudies evaluating the efficacy of pembrolizumab, both alone and in combination with chemotherapy or other investigational agents. Participants will first enroll in the master protocol and undergo screening to determine their eligibility for specific substudies based on their cancer characteristics and treatment history. The study utilizes a platform design to facilitate the evaluation of multiple treatment combinations in a structured manner.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has histologically- or cytologically-confirmed diagnosis of Stage IV squamous or nonsquamous NSCLC
* Has measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has an active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection requiring systemic therapy

Where it's running

• Dartmouth Hitchcock Medical Center ( Site 0016)
  Lebanon, New Hampshire, United States Recruiting
• Sanford Fargo Medical Center ( Site 0039)
  Fargo, North Dakota, United States Recruiting
• Ohio State University Comprehensive Cancer Center ( Site 0015)
  Columbus, Ohio, United States Recruiting
• Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
  Philadelphia, Pennsylvania, United States Recruiting
• Sanford Cancer Center ( Site 0038)
  Sioux Falls, South Dakota, United States Recruiting
• The University of Texas MD Anderson Cancer Center ( Site 0009)
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Combining adagrasib, pembrolizumab, and chemotherapy for lung cancer with a specific mutation

  This study is testing a new treatment combining adagrasib, pembrolizumab, and chemotherapy to see if it helps people with a specific type of lung cancer that has a KRAS G12C mutation.

  Recruiting at 303 sites Phase 3 Mirati Therapeutics Inc. · Birmingham, Alabama and 316 other locations · NCT06875310

• Comparing rilvegostomig and pembrolizumab for treating advanced lung cancer

  This study is testing whether a new drug called rilvegostomig works better than pembrolizumab for treating advanced lung cancer in patients whose tumors have a specific marker.

  Recruiting at 247 sites Phase 3 AstraZeneca · La Mesa, California and 303 other locations · NCT06868277

• Combining Sigvotatug Vedotin and Pembrolizumab for Non-Small Cell Lung Cancer

  This study is testing a new combination of two treatments, Sigvotatug Vedotin and pembrolizumab, to see if it helps people with advanced non-small cell lung cancer feel better compared to just using pembrolizumab alone.

  Recruiting at 355 sites Phase 3 Pfizer · Fullerton, California and 388 other locations · NCT06758401

• Combining pembrolizumab with intismeran autogene for non-small cell lung cancer treatment

  This study is testing if a new combination of a gene therapy and a cancer drug can help people with non-small cell lung cancer stay cancer-free after surgery.

  Recruiting at 234 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 245 other locations · NCT06623422

• Efficacy and safety of pembrolizumab with or without chemotherapy for advanced lung cancer

  This study is testing if adding pembrolizumab to chemotherapy helps people with advanced lung cancer feel better and live longer compared to using pembrolizumab alone.

  Recruiting at 16 sites Phase 1/2 Merck Sharp & Dohme LLC · Gilbert, Arizona and 46 other locations · NCT04165070

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.